Abstract
BackgroundThe treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data.MethodsA systematic search of the published data was conducted in PubMed Medline, EMBASE and Cochrane databases. Eligible studies were clinical trials, case-control studies or prospective cohort studies aiming at assessing the efficacy and safety of the SOF-containing regimens in patients co-infected with HCV and HIV. Heterogeneity of results was assessed and a pooled analysis was performed using random effects model with maximum likelihood estimate and 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were also performed. STATA 13.0 software was used to analyze the data.ResultsSeven studies (n = 1167 co-infected patients) were included in this analysis. The pooled estimate of sustained virological response at 12 weeks (SVR12) was 94.0% (95%CI: 92.0%–95.0%). Subgroup analysis showed that the treatment-naïve patients had higher SVR12 compared with patients that were treated before (χ2 = 21.39, P < 0.01). The pooled incidence of any adverse events (AEs) was 79.6% (95%CI: 77.1%–82.1%). Publication bias did not exist.ConclusionThe results of this study showed that the treatment response of SOF-containing regimens in patients co-infected with HIV and HCV was satisfied. Attention should be paid to the high rates of AEs.
Highlights
The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex
Published or unpublished studies were enrolled if they met the following criteria: (1) the study population were co-infected with HCV and HIV; (2) interventions included SOF; (3) the main outcome measure was sustained virological response at 12 weeks (SVR12); (4) the studies reported the number of patients who achieved and failed to achieve SVR12; (5) the studies showed the results of safety outcome
In this comprehensive meta-analysis of seven studies evaluating the efficacy and safety of SOF for treatment in HCV/HIV co-infected patients, we found that the SVR12 was 94.0% (95%confidence interval (CI): 92.0%–95.0%) and the rate of any adverse events (AEs) was 67.8% (95%CI: 52.8%–82.8%)
Summary
The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data. It’s estimated that up to 7 million patients are infected with both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) worldwide [1]. The. Li et al Virology Journal (2018) 15:19 studies of them have performed post-hoc analyses to evaluate the efficacy and safety of SOF with or without other DAAs in patients with certain characteristics. This study aims at summarizing the currently available data on treatment of HCV in HIV with SOF and to provide guidance in practical clinical algorithms of HCV/HIV co-infected patients’ management
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
